A Comparison of 111In-J591 SPECT with 89Zr-J591 PET Imaging for Prostate Cancer Patients
Chalasani, Sandhya ; Lindgren Belal, Sarah LU
; Fareedy, Shoaib B
; Spratt, Daniel E.
; Robinson, Brian D
; Osborne, Joseph R
; Bander, Neil H
and Scherr, Douglas S
(2014)
American Urological Association (AUA) Annual Meeting
In The Journal of urology
191(S4).
p.602-603
- Abstract
- Introduction and Objectives: To compare pilot cohorts of men scheduled for radical prostatectomy imaged with novel antibody conjugates: Cohort 1 (111In-J591) single photon emission tomography (SPECT) or Cohort 2 (89Zr-J591) positron emission tomorgraphy (PET).
Methods: 1) Cohort 1: Eight patients with abnormal digital rectal exam and biopsy proven prostate cancer were injected intravenously with two milligrams of J591 labeled with 5 mCi of 111In. SPECT/CT imaging was performed 2 to 5 days post injection. Prostatectomy was performed on the day of imaging and the excised prostate was imaged with SPECT/CT and planar scintigraphy before being sent to surgical pathology.
2) Cohort... (More) - Introduction and Objectives: To compare pilot cohorts of men scheduled for radical prostatectomy imaged with novel antibody conjugates: Cohort 1 (111In-J591) single photon emission tomography (SPECT) or Cohort 2 (89Zr-J591) positron emission tomorgraphy (PET).
Methods: 1) Cohort 1: Eight patients with abnormal digital rectal exam and biopsy proven prostate cancer were injected intravenously with two milligrams of J591 labeled with 5 mCi of 111In. SPECT/CT imaging was performed 2 to 5 days post injection. Prostatectomy was performed on the day of imaging and the excised prostate was imaged with SPECT/CT and planar scintigraphy before being sent to surgical pathology.
2) Cohort 2: Eleven patients were injected intravenously with 5 mCi 89Zr-J591 followed 6 days later by whole body PET imaging. Patients underwent surgery the day of PET imaging and the specimens were imaged by ex vivo PET and custom 3 Tesla magnetic resonance scanner coil. SPECT/PET imaging studies and histopathology were correlated.
Results: 111In-J591 whole body images showed the expected bio-distribution seen in other ongoing imaging/therapy trials for metastatic Prostate Cancer (PCa). Imuno-scintigraphic images were consistent with the pathologic diagnoses for all of the patients. In case of 89Zr-J591/PSMA PET imaging in localized PCa it is observed 89Zr-J591-PET binds to tumor foci in situ and binds primarily to Gleason ≥7 and larger sized tumors, likely corresponding to clinically significant disease that warrants definitive therapy.
Conclusions: 111In-J591 demonstrated targeting in localized disease in prostatectomy specimen, but pathologic validation was only inferred by quadrant due to low soft tissue contrast and the inherent resolution limits of the clinical scanner on a relatively small specimen. 89Zr-J591-PET can identify discrete intra-prostatic tumor foci, and in our cohort, visualized most of the index lesions. Additionally, high-grade tumors are generally better visualized with this novel imaging agent. There is a relationship between SUV on the 89Zr-J591-PET of tumor foci and their aggressiveness as defined by Gleason score. The preliminary data from this pilot study warrants further investigation with MicroSPECT and autoradiograph or ImmunoPET and MRI. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/93903ce4-60bf-49a5-a595-097ee7dc7ff4
- author
- Chalasani, Sandhya
; Lindgren Belal, Sarah
LU
; Fareedy, Shoaib B
; Spratt, Daniel E.
; Robinson, Brian D
; Osborne, Joseph R
; Bander, Neil H
and Scherr, Douglas S
- publishing date
- 2014-04-01
- type
- Contribution to journal
- publication status
- published
- in
- The Journal of urology
- volume
- 191
- issue
- S4
- pages
- 602 - 603
- publisher
- Lippincott Williams & Wilkins
- conference name
- American Urological Association (AUA) Annual Meeting
- conference location
- Orlando, United States
- conference dates
- 2014-05-16 - 2014-05-21
- ISSN
- 1527-3792
- DOI
- 10.1016/j.juro.2014.02.1670
- language
- English
- LU publication?
- no
- id
- 93903ce4-60bf-49a5-a595-097ee7dc7ff4
- date added to LUP
- 2022-12-13 21:17:48
- date last changed
- 2022-12-14 08:43:45
@misc{93903ce4-60bf-49a5-a595-097ee7dc7ff4,
abstract = {{<b>Introduction and Objectives:</b> To compare pilot cohorts of men scheduled for radical prostatectomy imaged with novel antibody conjugates: Cohort 1 (<sup>111</sup>In-J591) single photon emission tomography (SPECT) or Cohort 2 (<sup>89</sup>Zr-J591) positron emission tomorgraphy (PET).<br/><br/><b>Methods:</b> 1) Cohort 1: Eight patients with abnormal digital rectal exam and biopsy proven prostate cancer were injected intravenously with two milligrams of J591 labeled with 5 mCi of <sup>111</sup>In. SPECT/CT imaging was performed 2 to 5 days post injection. Prostatectomy was performed on the day of imaging and the excised prostate was imaged with SPECT/CT and planar scintigraphy before being sent to surgical pathology.<br/><br/>2) Cohort 2: Eleven patients were injected intravenously with 5 mCi <sup>89</sup>Zr-J591 followed 6 days later by whole body PET imaging. Patients underwent surgery the day of PET imaging and the specimens were imaged by ex vivo PET and custom 3 Tesla magnetic resonance scanner coil. SPECT/PET imaging studies and histopathology were correlated.<br/><br/><b>Results:</b> <sup>111</sup>In-J591 whole body images showed the expected bio-distribution seen in other ongoing imaging/therapy trials for metastatic Prostate Cancer (PCa). Imuno-scintigraphic images were consistent with the pathologic diagnoses for all of the patients. In case of <sup>89</sup>Zr-J591/PSMA PET imaging in localized PCa it is observed <sup>89</sup>Zr-J591-PET binds to tumor foci in situ and binds primarily to Gleason ≥7 and larger sized tumors, likely corresponding to clinically significant disease that warrants definitive therapy.<br/><br/><b>Conclusions:</b> <sup>111</sup>In-J591 demonstrated targeting in localized disease in prostatectomy specimen, but pathologic validation was only inferred by quadrant due to low soft tissue contrast and the inherent resolution limits of the clinical scanner on a relatively small specimen. <sup>89</sup>Zr-J591-PET can identify discrete intra-prostatic tumor foci, and in our cohort, visualized most of the index lesions. Additionally, high-grade tumors are generally better visualized with this novel imaging agent. There is a relationship between SUV on the <sup>89</sup>Zr-J591-PET of tumor foci and their aggressiveness as defined by Gleason score. The preliminary data from this pilot study warrants further investigation with MicroSPECT and autoradiograph or ImmunoPET and MRI.}},
author = {{Chalasani, Sandhya and Lindgren Belal, Sarah and Fareedy, Shoaib B and Spratt, Daniel E. and Robinson, Brian D and Osborne, Joseph R and Bander, Neil H and Scherr, Douglas S}},
issn = {{1527-3792}},
language = {{eng}},
month = {{04}},
note = {{Conference Abstract}},
number = {{S4}},
pages = {{602--603}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{The Journal of urology}},
title = {{A Comparison of <sup>111</sup>In-J591 SPECT with <sup>89</sup>Zr-J591 PET Imaging for Prostate Cancer Patients}},
url = {{http://dx.doi.org/10.1016/j.juro.2014.02.1670}},
doi = {{10.1016/j.juro.2014.02.1670}},
volume = {{191}},
year = {{2014}},
}